<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="systematic-review" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2024.1327851</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Systematic Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Recent status and trends of nanotechnology in cervical cancer: a systematic review and bibliometric analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Song</surname>
<given-names>Xiangzhi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Xun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tan</surname>
<given-names>Zhiwei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Lushun</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2010354"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>School of Clinical Medicine, Chengdu Medical College</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Pathology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Development and Regeneration Key Laboratory of Sichuan Province, Department of Neurobiology, Chengdu Medical College</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Pathology and Pathophysiology, Chengdu Medical College</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Qitong Huang, Gannan Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Sadanand Pandey, Yeungnam University, Republic of Korea</p>
<p>Shirong Hu, Minnan Normal University, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Zhiwei Tan, <email xlink:href="mailto:4658624@qq.com">4658624@qq.com</email>; Lushun Zhang, <email xlink:href="mailto:zhangls2012@cmc.edu.cn">zhangls2012@cmc.edu.cn</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>02</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>14</volume>
<elocation-id>1327851</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>10</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>01</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Song, Li, Tan and Zhang</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Song, Li, Tan and Zhang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Cervical cancer is currently the second leading cause of cancer death among women from developing countries (<xref ref-type="bibr" rid="B1">1</xref>). However, there is a lack of effective treatment methods, and the existing treatments often result in significant adverse reactions and high chances of recurrence, which ultimately impact the prognosis of patients. As a result, the application of nanotechnology, specifically nanoparticle-based approaches, in the diagnosis and treatment of cervical cancer has gained significant attention.&#xa0;This study aims to examine the current research status and future development trends of nanotechnology in relation to cervical cancer using a bibliometric perspective.</p>
</sec>
<sec>
<title>Methods</title>
<p>A bibliometric analysis was performed to gather relevant research papers from the Web of Science database. VOSviewer and CiteSpace were utilized to conduct quantitative analysis and identify hot topics in the field, focusing on countries, institutions, journals, authors, and keywords.</p>
</sec>
<sec>
<title>Result</title>
<p>A total of 997 eligible literature were retrieved. From January 1, 2014 to September 20, 2023, the overall number of publications showed an upward trend. The paper mainly comes from China (n=414). The main institution is the Chinese Academy of Sciences (n=62), and 60% of the top 10 institutions in the number of documents issued are from China. First authors Ma, Rong (n=12) and Alifu, Nuernisha (n=12). The journal with the highest publication volume is ACS Applied Materials&amp;INTERFACES (n=35), and the journal with the highest citation frequency is BIOMATERIALS (n=508). &#x201c;Nanoparticles (n=295)&#x201d;, &#x201c;cervical cancer (n=248)&#x201d;, and &#x201c;drug delivery (n=218)&#x201d; are the top three most frequently occurring keywords. In recent years, photothermal therapy and indocyanine green have become research hotspots.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The application of nanotechnology in the field of cervical cancer has garnered considerable attention. Nanoparticles-based methods for diagnosis, administration, and treatment have proven to be instrumental in enhancing the sensitivity of cervical cancer detection, improving the accuracy and efficiency of administration, and reducing drug toxicity. Enhancing treatment efficacy and improving patient prognosis have emerged as current research priorities and future directions.</p>
</sec>
</abstract>
<kwd-group>
<kwd>nanotechnology</kwd>
<kwd>cervical cancer</kwd>
<kwd>bibliometrics</kwd>
<kwd>nanoparticles</kwd>
<kwd>drug deliver</kwd>
</kwd-group>
<counts>
<fig-count count="6"/>
<table-count count="5"/>
<equation-count count="0"/>
<ref-count count="76"/>
<page-count count="15"/>
<word-count count="7719"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Gynecological Oncology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Globally, cervical cancer is the fourth most common type of cancer among women and the second leading cause of cancer-related deaths among women from developing countries (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). The majority of cervical cancers are caused by human papillomavirus (HPV), a virus similar to the human immunodeficiency virus. HPV poses the highest risk for cervical cancer and can only be managed through a limited number of highly invasive methods (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). While chemotherapy and surgery have been proven highly effective in treating early-stage cervical cancer, surgery is still the preferred option due to potential damage to the female reproductive system caused by chemotherapy. Chemotherapy remains effective for those with more advanced conditions (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). However, incomplete surgical resection, adverse reactions to chemotherapeutic agents, and cellular resistance to multiple drugs can lead to unsatisfactory long-term results. Additionally, the complex nature of tumor cells and the harsh tumor microenvironment make them resistant to treatment and metastasis, posing a significant obstacle to the possibility of recurrent cervical cancer. This could be due to remaining tumor cells or metastatic tumor cells (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). Therefore, there is an urgent need for a more effective method to diagnose early-stage cervical carcinogenesis, improve the efficacy of drug action, reduce adverse effects, and enhance the quality of prognosis.</p>
<p>In comparison to other diagnostic modalities, various nanoparticle-based measurements in nanotechnology have demonstrated improved selectivity and sensitivity, as well as provided support for obtaining information that traditional measurements cannot. By leveraging the exceptional optical and electrical properties of nanomaterials, such as gold nanoparticles, along with their significantly larger surface area, they can be integrated with various types of sensors, including electrochemical sensors and DNA biosensors, to effectively detect biomarkers. This approach successfully addresses the limitations of traditional sensors, such as low conductivity, low sensitivity, and high cost (<xref ref-type="bibr" rid="B8">8</xref>&#x2013;<xref ref-type="bibr" rid="B11">11</xref>). This enables early detection of tumor onset and timely intervention, ultimately aiming to enhance patient survival. Nanoparticles can also be utilized to monitor disease progression in patients, facilitating the formulation of more precise treatment strategies (<xref ref-type="bibr" rid="B12">12</xref>). Depending on the characteristics of the tumor microenvironment, such as hypoxia and acidity, nanoparticles can be designed to respond effectively in various environments, thereby enhancing treatment outcomes. By modifying the properties of nanoparticles, they can facilitate the uptake of drugs into the tumor tissue of the uterine cervix, increase their concentration in tumor tissue, and improve treatment efficacy. In addition, nanoparticles can be used as efficient carriers for drug delivery due to their good biocompatibility, permeability, and retention. Utilizing nanoparticles as delivery systems for anticancer agents can enhance drug efficacy, reduce dosing and treatment frequency, and potentially minimize the toxicity of antitumor drugs to the human body (<xref ref-type="bibr" rid="B13">13</xref>). With the deepening of research on nanotechnology, researchers have also designed some progressively stimuli-responsive drug delivery systems based on this foundation, which can enhance drug delivery more effectively (<xref ref-type="bibr" rid="B14">14</xref>). Furthermore, certain nanoparticles can be employed as specific markers targeting cancer cells (<xref ref-type="bibr" rid="B15">15</xref>). For example, using exosomes isolated from the tumors of cervical cancer patients as nanocarriers to transport drugs can robustly target the target cells (<xref ref-type="bibr" rid="B16">16</xref>). The development of nanotechnology has significantly enhanced various aspects of medicine, particularly in the field of cancer diagnosis and treatment, where improved diagnostic methods and novel drug delivery systems hold great promise (<xref ref-type="bibr" rid="B17">17</xref>). The combination of nanotechnology and cervical cancer research may yield unexpected advancements in the future.</p>
<p>Currently, there is no research analyzing the application of nanotechnology in cervical cancer using the bibliometrics approach. Bibliometrics involves analyzing published information, such as books, journal articles, and data sets, along with their associated metadata like abstracts, keywords, and citations. It also includes using statistical information to describe the relationship between published works. Tools like VOSviewer and CiteSpace can be used to visualize and analyze academic literature in this research field (<xref ref-type="bibr" rid="B18">18</xref>). By employing bibliometrics, we can gain a better understanding of existing research, identify current areas of interest, and predict future trends in nanotechnology for cervical cancer. The objective of this study is to conduct a comprehensive analysis of the trends of nanotechnology in cervical cancer from various angles using bibliometric tools. This analysis will identify the prominent countries, journals, institutions, and authors that have contributed to this field. Additionally, the study will focus on analyzing and discussing the current research areas of interest and potential future research directions. The findings will be beneficial for researchers seeking to gain a deeper understanding of this field or for those who are new to it.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Data source and collection</title>
<p>The Web Science Core Collection (WoSCC) is a widely used bibliometric analysis database that contains over 10,000 high-quality journals and comprehensive citation records (<xref ref-type="bibr" rid="B19">19</xref>). Additionally, WoSCC has been found to have more accurate document type labeling compared to other databases (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>).</p>
<p>
<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref> illustrates the workflow for this study. In September 2023, we conducted a search for original research articles related to nanotechnology for cervical cancer that were published between January 1, 2014, and September 20, 2023. To ensure inclusivity and eliminate irrelevant articles, we designed a search strategy that involved the following steps: 1) Using keywords such as &#x2018;cervical cancer&#x2019; and &#x2018;nanotechnology&#x2019;; 2) Including various synonyms for these keywords, including specific names of nanomaterials and nanoparticles; 3) Excluding papers that were not original research; 4) Limiting the search to English publications only; 5) Focusing on the data categories of &#x2018;articles&#x2019; and &#x2018;reviews&#x2019;. After applying these criteria, we evaluated the title and abstract of each article to determine its relevance to the topic. In cases where the literature was inconclusive, two researchers read the full text and conducted a more detailed evaluation to ensure accurate results. Subsequently, we identified pertinent articles and extracted primary data on nations/regions, institutions, authors, journals, and key terms. For the specific search formula used in this article, please refer to <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Materials 1</bold>
</xref>.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Flow chart of literature selection.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1327851-g001.tif"/>
</fig>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Data analysis and visualization</title>
<p>The collected literature was analyzed using CiteSpace, which provided insights into authors, countries, institutions, journals, and keywords. To visualize keyword co-occurrence, VOSviewer was employed, representing authors or keywords as nodes with varying sizes based on their frequency. The strength of connections was depicted by line thickness, while node colors indicated different clusters or periods. The Scimago Graphica tool was utilized to visualize the overall distribution of publications.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Annual publications and trends</title>
<p>To some extent, the number of publications can represent the heat and development of the field in a given time. From January 1, 2014 to September 20, 2023, WOS received a total of 997 publications on nanotechnology in cervical cancer research, including 941 articles and 56 reviews. <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref> shows the worldwide trend in number of publications per year and total number of publications for research in cervical cancer for the period January 2014 to September 2023. Each year of the decade, the number of articles published was close to 100, with occasional declines in the intervening years, with an average annual growth rate of 2.39%.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Annual Publications and Trends.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1327851-g002.tif"/>
</fig>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Contributions of authors</title>
<p>There were 5566 authors included in the study, with the <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> showing the top ten authors and co-citations. Ma, Rong (n=12) and Alifu, Nuernisha (n=12) had the highest number of articles published, followed by Yan, Ting (n=11), Alimu, Gulinigaer (n=11). The CiteSpace was used to show the referencing relationships between different authors (<xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Material Figure&#xa0;1A</bold>
</xref>). Nodal sizes represent the number of papers, and rows represent connections between authors. Co-citation means that two or more authors are cited simultaneously in one or more articles, and that these two or more authors form a co-citation relationship. Overall, 27787 authors were cited at least once (data obtained from VOSviewer). WANG Y (n=73) is the most cited author of the network built by CiteSpace, LIU Y is the author with the highest centrality (0.18), ranking fifth in terms of publication volume and considerable output (The network of co-cited author relationships can be found in the <xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Material Figure&#xa0;1B</bold>
</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Contributions of authors.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="left">Rank</th>
<th valign="middle" rowspan="2" align="left">Author</th>
<th valign="middle" rowspan="2" align="left">Documents</th>
<th valign="middle" rowspan="2" align="left">Burst</th>
<th valign="middle" rowspan="2" align="left">Co-cited Author</th>
<th valign="middle" rowspan="2" align="left">Documents</th>
<th valign="middle" rowspan="2" align="left">Centrality</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">Ma, Rong</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">3.59</td>
<td valign="middle" align="left">WANG Y</td>
<td valign="middle" align="left">73</td>
<td valign="middle" align="left">0.13</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">Alifu, Nuernisha</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">3.59</td>
<td valign="middle" align="left">ZHANG Y</td>
<td valign="middle" align="left">71</td>
<td valign="middle" align="left">0.14</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">Yan, Ting</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">3.26</td>
<td valign="middle" align="left">ZHANG L</td>
<td valign="middle" align="left">54</td>
<td valign="middle" align="left">0.11</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">Alimu, Gulinigaer</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">3.26</td>
<td valign="middle" align="left">LI L</td>
<td valign="middle" align="left">52</td>
<td valign="middle" align="left">0.14</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">Zhu, Lijun</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">4.16</td>
<td valign="middle" align="left">LIU Y</td>
<td valign="middle" align="left">50</td>
<td valign="middle" align="left">0.18</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Du, Zhong</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">2.96</td>
<td valign="middle" align="left">WANG L</td>
<td valign="middle" align="left">47</td>
<td valign="middle" align="left">0.09</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Zhang, Xueliang</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">4.16</td>
<td valign="middle" align="left">WANG J</td>
<td valign="middle" align="left">45</td>
<td valign="middle" align="left">0.15</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Xie, Zhigang</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">MAEDA H</td>
<td valign="middle" align="left">44</td>
<td valign="middle" align="left">0.05</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Liu, Shi</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">CHEN Y</td>
<td valign="middle" align="left">41</td>
<td valign="middle" align="left">0.14</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Chen, Shuang</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">3.74</td>
<td valign="middle" align="left">FERLAY J</td>
<td valign="middle" align="left">41</td>
<td valign="middle" align="left">0.09</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Top ten authors and co-citing authors of studies on nanotechnology and cervical cancer.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Contributions of countries or regions</title>
<p>Research on nanotechnology/nanomaterials in cervical cancer has been conducted in 164 countries/regions over the last decade. On the country distribution map (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>, the darker the color of the country, the more publications there are.), the top three countries/regions are China (n = 414,41.52%), India (n = 208, 20.86%) and the United States (n = 93, 9.32%) on the basis of the number of publications. The cooperation between many countries can be seen in <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>, with the cooperation between China and India being the most evident. We then conducted a more in-depth analysis of high productivity countries in the field, and publications from the top 10 countries are shown in <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref> and <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>. China was the country with the most publications, the United States had the highest average number of citations with a total of 33.13 citations. The degree of centrality is an assessment of the importance of the nodes in the network, primarily used to measure the value of nodes&#x2019; bridge functions across the network structure. The purple circles outside each node in <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref> represent the centrality of each country. Among the top 10 countries in the world, the United States has the highest betweenness centrality of 0.34, followed by China (0.25). Although Spain (0.23) did not have a large number of publications, their central values are high. Which shows that they play an essential role in international co-operation. The size of the circle in the visualization diagram built by CiteSpace represents the number of papers published, the thick line indicates cooperation between countries/regions and the width of the purple node ring represents the size of the central value.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>
<bold>(A)</bold> Geographical distribution map based on the total publications of different countries/regions. <bold>(B)</bold> The international collaborations&#x2019; visualization map of countries/regions. <bold>(C)</bold> The countries/regions&#x2019; citation network visualization map was generated by using Citespace. The size of the circle in the visualization diagram built by citespace represents the number of papers published,and the thickness of the purple ring of the node represents the size of the center value.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1327851-g003.tif"/>
</fig>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Contributions of countries/regions.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="left">Rank</th>
<th valign="middle" rowspan="2" align="left">Countries/regions</th>
<th valign="middle" rowspan="2" align="left">Count</th>
<th valign="middle" rowspan="2" align="left">Centrality</th>
<th valign="middle" rowspan="2" align="left">Citations</th>
<th valign="middle" rowspan="2" align="left">Average Citations/Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">CHINA</td>
<td valign="middle" align="left">414</td>
<td valign="middle" align="left">0.25</td>
<td valign="middle" align="left">10723</td>
<td valign="middle" align="left">25.90</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">INDIA</td>
<td valign="middle" align="left">208</td>
<td valign="middle" align="left">0.13</td>
<td valign="middle" align="left">4818</td>
<td valign="middle" align="left">23.16</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">USA</td>
<td valign="middle" align="left">93</td>
<td valign="middle" align="left">0.34</td>
<td valign="middle" align="left">3081</td>
<td valign="middle" align="left">33.13</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">SOUTH KOREA</td>
<td valign="middle" align="left">73</td>
<td valign="middle" align="left">0.01</td>
<td valign="middle" align="left">2249</td>
<td valign="middle" align="left">30.81</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">SAUDI ARABIA</td>
<td valign="middle" align="left">56</td>
<td valign="middle" align="left">0.13</td>
<td valign="middle" align="left">1247</td>
<td valign="middle" align="left">22.27</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">IRAN</td>
<td valign="middle" align="left">47</td>
<td valign="middle" align="left">0.16</td>
<td valign="middle" align="left">1131</td>
<td valign="middle" align="left">24.06</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">TURKEY</td>
<td valign="middle" align="left">27</td>
<td valign="middle" align="left">0.06</td>
<td valign="middle" align="left">477</td>
<td valign="middle" align="left">17.67</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">MEXICO</td>
<td valign="middle" align="left">27</td>
<td valign="middle" align="left">0.05</td>
<td valign="middle" align="left">364</td>
<td valign="middle" align="left">13.48</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">SPAIN</td>
<td valign="middle" align="left">23</td>
<td valign="middle" align="left">0.23</td>
<td valign="middle" align="left">514</td>
<td valign="middle" align="left">22.35</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">BRAZIL</td>
<td valign="middle" align="left">22</td>
<td valign="middle" align="left">0.02</td>
<td valign="middle" align="left">426</td>
<td valign="middle" align="left">19.36</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Top ten countries/regions for related publications.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Contributions of institutions</title>
<p>Articles/comments received from the WOS are from 3229 different institutions. On the basis of the number of publications, <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref> comprises the top ten production agencies. It is not hard to see from table that six institutions are from China, with two institutions from India, one from Saudi Arabia and one from France. The United States has the highest number of citations and the third-highest number of publications, but none of the top ten publications are from it. The Chinese Academy of Sciences(n=62) has the largest number of publications and Indian Institute of Technology System (IIT System) has the highest centrality (0.2). The size of the circle in the visual map of CiteSpace (<xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Material Figure&#xa0;2</bold>
</xref>) represents the number of articles published by each institution, each row represents the collaboration between the two institutes, and the purple circle represents the node with a higher centrality, the higher the number, the greater the centrality. The top 10 universities published 239 articles, or 23.97% of the total, greatly promoted the development of fields related to the subject.</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Contributions of institutions.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Institutions</th>
<th valign="middle" align="left">Count</th>
<th valign="middle" align="left">Centrality</th>
<th valign="middle" align="left">Country</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">Chinese Academy of Sciences</td>
<td valign="middle" align="left">62</td>
<td valign="middle" align="left">0.12</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">Indian Institute of Technology System (IIT System)</td>
<td valign="middle" align="left">47</td>
<td valign="middle" align="left">0.2</td>
<td valign="middle" align="left">India</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">Changchun Institute of Applied Chemistry</td>
<td valign="middle" align="left">24</td>
<td valign="middle" align="left">0.03</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">King Saud University</td>
<td valign="middle" align="left">19</td>
<td valign="middle" align="left">0.14</td>
<td valign="middle" align="left">Saudi Arabia</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">University of Chinese Academy of Sciences</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">0.1</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Indian Institute of Science Education &amp; Research (IISER) Pune</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">0.01</td>
<td valign="middle" align="left">India</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Xinjiang Medical University</td>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">0.04</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Jilin University</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Centre National de la Recherche Scientifique (CNRS)</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">0.09</td>
<td valign="middle" align="left">France</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Zhejiang University</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">0.01</td>
<td valign="middle" align="left">China</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Top ten institutions for related publications.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Analysis of journals/co-cited journals</title>
<p>332 journals have published papers on nanotechnology and hepatic cancer, of which ACS APPLIED MATERIALS &amp; INTERFACES (n = 35, IF 2022&#xa0;=&#xa0;9.5) ranks first and JOURNAL OF MATERIALS CHEMISTRY B (n =34, IF 2022&#xa0;=&#xa0;7) ranked second. RSC ADVANCES (n = 32, IF 2022&#xa0;=&#xa0;3.9) ranked third. Of the top ten journals, 30% (3/10) are from Netherlands and 30% (3/10) are from the England. JOURNAL OF CONTROLLED RELEASE (n = 18, IF 2022&#xa0;=&#xa0;10.8) was the journal with the largest impact factor. The details are shown in <xref ref-type="table" rid="T4a">
<bold>Table&#xa0;4A</bold>
</xref>.</p>
<table-wrap id="T4a" position="float">
<label>Table&#xa0;4A</label>
<caption>
<p>Journal analysis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Journals</th>
<th valign="middle" align="left">Documents</th>
<th valign="middle" align="left">IF2022</th>
<th valign="middle" align="left">JCR</th>
<th valign="middle" align="left">Country</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">ACS APPLIED MATERIALS &amp; INTERFACES</td>
<td valign="middle" align="left">35</td>
<td valign="middle" align="left">9.5</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="left">UNITED STATES</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">JOURNAL OF MATERIALS CHEMISTRY B</td>
<td valign="middle" align="left">34</td>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="left">ENGLAND</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">RSC ADVANCES</td>
<td valign="middle" align="left">32</td>
<td valign="middle" align="left">3.9</td>
<td valign="middle" align="left">Q2</td>
<td valign="middle" align="left">ENGLAND</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">COLLOIDS AND SURFACES B-BIOINTERFACES</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">5.8</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="left">NETHERLANDS</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">INTERNATIONAL JOURNAL OF NANOMEDICINE</td>
<td valign="middle" align="left">19</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="left">NEW ZEALAND</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">NANOSCALE</td>
<td valign="middle" align="left">19</td>
<td valign="middle" align="left">6.7</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="left">ENGLAND</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">JOURNAL OF CONTROLLED RELEASE</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">10.8</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="left">NETHERLANDS</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">8.2</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="left">NETHERLANDS</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">5.6</td>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="left">UNITED STATES</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">SCIENTIFIC REPORTS</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">4.6</td>
<td valign="middle" align="left">Q2</td>
<td valign="middle" align="left">ENGLAND</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Top ten journals for related publications.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Among the co-cited journals, BIOMATERIALS (n = 508, IF 2022&#xa0;=&#xa0;14) ranked first, ACS NANO (n = 440, IF 2022&#xa0;=&#xa0;17.1) ranked second. J CONTROL RELEASE (n = 419, IF 2022&#xa0;=&#xa0;3.9) was ranked third but had the largest centrality. The details are shown in <xref ref-type="table" rid="T4b">
<bold>Table&#xa0;4B</bold>
</xref>.</p>
<table-wrap id="T4b" position="float">
<label>Table&#xa0;4B</label>
<caption>
<p>Journal analysis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Co-cited journals</th>
<th valign="middle" align="left">Count</th>
<th valign="middle" align="left">Centrality</th>
<th valign="middle" align="left">IF2022</th>
<th valign="middle" align="left">JCR</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">BIOMATERIALS</td>
<td valign="middle" align="left">508</td>
<td valign="middle" align="left">0.03</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Q1</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">ACS NANO</td>
<td valign="middle" align="left">440</td>
<td valign="middle" align="left">0.02</td>
<td valign="middle" align="left">17.1</td>
<td valign="middle" align="left">Q1</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">J CONTROL RELEASE</td>
<td valign="middle" align="left">419</td>
<td valign="middle" align="left">0.03</td>
<td valign="middle" align="left">3.9</td>
<td valign="middle" align="left">Q2</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">INT J NANOMED</td>
<td valign="middle" align="left">393</td>
<td valign="middle" align="left">0.01</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Q2</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">ADV DRUG DELIVER REV</td>
<td valign="middle" align="left">357</td>
<td valign="middle" align="left">0.02</td>
<td valign="middle" align="left">16.1</td>
<td valign="middle" align="left">Q1</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">ACS APPL MATER INTER</td>
<td valign="middle" align="left">352</td>
<td valign="middle" align="left">0.01</td>
<td valign="middle" align="left">9.5</td>
<td valign="middle" align="left">Q2</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">J AM CHEM SOC</td>
<td valign="middle" align="left">344</td>
<td valign="middle" align="left">0.01</td>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">Q1</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">NANOSCALE</td>
<td valign="middle" align="left">343</td>
<td valign="middle" align="left">0.01</td>
<td valign="middle" align="left">6.7</td>
<td valign="middle" align="left">Q2</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">COLLOID SURFACE B</td>
<td valign="middle" align="left">332</td>
<td valign="middle" align="left">0.01</td>
<td valign="middle" align="left">5.8</td>
<td valign="middle" align="left">Q1</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">ADV MATER</td>
<td valign="middle" align="left">293</td>
<td valign="middle" align="left">0.01</td>
<td valign="middle" align="left">29.4</td>
<td valign="middle" align="left">Q1</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Top ten co-cited journals for related publications.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>Analysis of keywords</title>
<p>Keywords condense the heart and essence of the paper, and through analysis of the co-occurrence of keywords can reveal the research hotspot of a certain scientific field. For example, in a visual network constructed using CiteSpace (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>), the larger the circular node, the greater the number of keywords, and the more representative the hotspot. The nodal line indicates the strength of the association, and the thicker the nodal line, the stronger the connection between them. The highest frequency was observed in nanoparticles (n=295), followed by cervical cancer (n=248) and drug-delivery (n=218) as detailed in <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material Table&#xa0;1</bold>
</xref>.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>
<bold>(A)</bold> Citespace visualization map of keywords. <bold>(B)</bold> CiteSpace visualization map of the top 20 keywords for the strongest citation bursts from January 2014 to September 2023 <bold>(C)</bold> VOSviewer visualization map of Cluster view of keywords. Different colors indicate different clusters.  (Source: <uri xlink:href="https://www.vosviewer.com/">https://www.vosviewer.com/</uri>).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1327851-g004.tif"/>
</fig>
<p>The shortest outbreak duration based on the keyword outbreak map is 3 years, citing the top 25 keywords with the highest outbreak intensity (Details can be found in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>). From <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>, keywords such as &#x201c;oxide (2014&#x2013;2016)&#x201d;, &#x201c;polymeric micelles (2014-1017)&#x201d; and &#x201c;gene delivery (2016-2018)&#x201d; have been given more attention in the past. &#x201c;extract (2021-2023)&#x201d;, &#x201c;indocyanine green (2021-2023)&#x201d; and &#x201c;photothermal therapy (2021-2023)&#x201d; have received widespread attention recently. It may be a new direction for future research.</p>
<p>We used VOSviewer to create a view of the keyword co-occurrence network for 4250 documents and select 82 keywords that have a frequency greater than or equal to 20 for visualization (Details can be found in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4C</bold>
</xref>). Each of the three colors in the picture represents a different cluster, referred to as a research topic. In addition, in the figure, we find that the identified keywords are divided into three clusters: red, green and blue. Red indicates clustering keywords related to drug, including nanoparticles, in-vitro, cisplatin, paclitaxel, etc. The keywords of the green group are primarily bound up with the drug-delivery, including photothermal therapy, fluorescence, targeted delivery, etc. The blue areas are mainly related to cytotoxicity, including gold nanoparticles,silver nanoparticles, green synthesis and so on.</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<sec id="s4_1">
<label>4.1</label>
<title>General information</title>
<p>The number of annual publications and the total number of publications are both increasing, indicating a growing interest in the application of nanotechnology in cervical cancer research. The involvement of researchers in this field is also on the rise.</p>
<p>In terms of the number of articles published, China, India, and the United States ranked in the top three, suggesting their overall strength in this area. Among the major publishers, six out of the top ten are from China. The institutions with the highest number of published articles are CAS, Indian Institute of Technology System, and Changchun Institute of Applied Chemistry. However, global cooperation among institutions in this field remains uncommon. Future studies will explore the benefits of strengthening international cooperation between countries and institutions for the continued development of the field.</p>
<p>The majority of nanotechnology and cervical cancer-related journals are published in ACS APPLIED MATERIALS &amp; INTERFACES, JOURNAL OF MATERIALS CHEMISTRY B, and RSC ADVANCES, with impact factors of 9.5, 7, and 3.9, respectively. BIOMATERIALS, ACS NANO, and J CONTROL RELEASE are the three most cited journals. These high-quality journals provide significant support for research in the field and indicate that biological/applied materials are not only the current hotspot but also the future development trend.</p>
<p>Out of the 23,556 researchers, Ma, Rong and Alifu, Nuernisha have published the most articles, followed by Yan, Ting and Alimu, Gulinigaer. Which shows that they are leading researchers in their current field.</p>
</sec>
<sec id="s4_2">
<label>4.2</label>
<title>Research hotspots</title>
<p>By analyzing the frequency of occurrence of keywords, it can reflect the hotspot of research and the trend of nanotechnology development in the application of cervical cancers. From the keyword analysis, it can be seen that the combination of nanoparticles and cervical cancer is a hot topic in current research.</p>
<sec id="s4_2_1">
<label>4.2.1</label>
<title>Nanoparticles in the field of cervical cancer</title>
<p>The increasing number of cervical cancer cases among women highlights the need to improve diagnostic methods and determine the stage of the disease. Nanotechnology has emerged as a promising field, allowing the utilization of nanomaterials in various diagnostic procedures. This utilization is driven by the unique physical characteristics of nanomaterials, which enhance the precision of diagnosis and the effectiveness of treatment. Therefore, the application of nanotechnology in the diagnosis and treatment of cervical cancer in women holds great potential to significantly improve the efficiency and accuracy of detection and therapy, providing valuable time for subsequent treatment.</p>
<sec id="s4_2_1_1">
<label>4.2.1.1</label>
<title>Role of nanotechnology in HPV virus detection</title>
<p>Based on empirical evidence, it has been established that high-risk variants of HPV exhibit a strong correlation with the onset of cervical cancer, as approximately 96% of cervical cancer cases are associated with these variants (<xref ref-type="bibr" rid="B22">22</xref>). Consequently, the precise identification of the HPV virus plays a pivotal role in both the prevention and early diagnosis of cervical cancer. Traditional methods for detecting HPV infection encompass the Pap test, visual inspection with acetic acid, and HPV serologic testing; however, these methods are hindered by their considerable expenses and limited specificity, thereby necessitating further enhancements (<xref ref-type="bibr" rid="B23">23</xref>). In this particular context, the utilization of nanomaterials&#x2019; exceptional properties holds promise for the development of diverse biosensors and electrosensors. These advanced sensors have the potential to enable rapid, accurate, and convenient detection of the HPV virus. Furthermore, they can enhance the sensitivity of detection by accurately identifying specific DNA and mRNA within the HPV virus. Gold nanoparticles are frequently employed in diverse sensor applications owing to their distinctive physicochemical properties, facile synthesis, surface functionalization, capabilities, and the ability to tune their optical properties based on size and shape (<xref ref-type="bibr" rid="B24">24</xref>); Moreover, graphene emerges as a highly efficient sensing technique for rapid detection through integration, with its functional groups demonstrating exceptional reliability in capturing molecules and analyzing their interactions with specific targets (<xref ref-type="bibr" rid="B25">25</xref>). Researchers have made significant progress in developing sensors using nanomaterials for HPV virus detection. One such example is the electrochemical DNA-biosensor developed by Pegah Mahmoodir et&#xa0;al. This biosensor utilizes the unique properties of the GO honeycomb structure, including high surface area, high electrical conductivity, and high chemical stability. Additionally, the incorporation of gold nanoparticles (AuNPs) enhances the electrical conductivity and creates immobilized channels for DNA on the electrode surface. The experiments conducted with this biosensor have demonstrated reliable results (<xref ref-type="bibr" rid="B26">26</xref>). In addition to genetic detection of HPV viruses, nanomaterials can also be used to detect HPV-associated proteins. Nanoparticles such as AuNPs have plasmon resonance (LSPR) properties, which allow them to be ionized under laser irradiation. This ionization generates characteristic mass reporter ions, making AuNPs suitable as mass labels for signal amplification. Additionally, by coupling antibodies to the nanoparticles, specific antigens can be targeted and marker proteins can be detected (<xref ref-type="bibr" rid="B27">27</xref>). Toby Siu-Chung Tam et&#xa0;al. utilized the property of AuNPs to develop an antibody-coupled AuNPs mass tag for the detection of HPV18E7 protein, enabling early cervical cancer diagnosis (<xref ref-type="bibr" rid="B28">28</xref>). Currently, the focus of nanomaterial application lies primarily on AuNPs, but there are still numerous other nanomaterials that require further study. Moreover, the combination of nanomaterials with other nanomaterials or molecules results in multifunctional nanoparticle couplings. These couplings possess both the physicochemical properties of the nanoparticles themselves and the functions of the couplings, thereby significantly enhancing the accuracy of nanoparticle diagnosis. This area of research remains a prominent and active field. With the continuous advancements in nanotechnology, there is immense potential to utilize various high-performance nanomaterials for the detection of HPV virus and the diagnosis of cervical cancer.</p>
</sec>
<sec id="s4_2_1_2">
<label>4.2.1.2</label>
<title>The role of nanotechnology in the detection of tumor markers for cervical cancer</title>
<p>Tumor markers are molecules that indicate the presence or prognosis of malignant tumors and can be used for the early diagnosis of tumorigenesis and recurrence, as well as to determine tumor prognosis and treatment efficacy (<xref ref-type="bibr" rid="B29">29</xref>). Currently, the application of nanotechnology in the detection of tumor markers is mainly to combine various types of nanoparticles with sensors and use their unique physicochemical properties to improve the accuracy of detection. Common tumor markers for cervical cancer include squamous cell carcinoma antigen (SCCA) and carcinoembryonic antigen (CEA), as well as other characteristic proteins and genes. SCCA is a glycoprotein that shows significantly elevated levels in patients with cervical cancer. It is considered as one of the suitable biomarkers for the detection of cervical cancer (<xref ref-type="bibr" rid="B30">30</xref>). Therefore, it is crucial to identify and quantify the critical level of SCCA for effective detection and treatment of cervical cancer. In addition the serum concentration of SCCA correlates with tumor stage, treatment outcome, recurrence and survival in patients with squamous cell cervical cancer (<xref ref-type="bibr" rid="B31">31</xref>). Therefore, an effective detection method is of particular importance in identifying and quantifying the severity of gynecological tumors. Xinmei Liu et&#xa0;al. utilized the high sensitivity of gold nanoparticles coupled to analyte molecules to detect and quantify SCCA levels (<xref ref-type="bibr" rid="B32">32</xref>). This method has demonstrated exceptional sensitivity in experiments and significantly aided in the detection of cervical cancer. Additionally, the abnormal methylation of genes in the promoter regions of tumor suppressor genes can impede DNA transcription, which is a critical process in tumors (<xref ref-type="bibr" rid="B33">33</xref>). Thus, methylation of genes may also be a biomarker for cervical cancer detection. Jin Huang et&#xa0;al. exploited the property that the transition of AuNPs from the dispersed to the aggregated state can lead to the discoloration of colloidal solutions. They employed this characteristic to develop a novel colorimetric detection method for identifying methylation of the PAX1 gene in cervical scrapings. This was achieved by combining sulfhydryl-labeled primers with AuNPs (<xref ref-type="bibr" rid="B34">34</xref>). Through a clinical trial of 42 patients with cervical cancer, the study found that the percentage of normal median methylation rate detected was 33.11%, while the percentage of CIN1 type median methylation rate detected was 45.14%. Additionally, the percentage of CIN2 type median methylation rate was 74.64%, the percentage of CIN3 type median methylation rate was 67.81%, and the percentage of SCC series median methylation rate was 82.64%. These results indicate a positive correlation between the methylation status and frequency of PAX1 with the severity of cervical cancer. Moreover, the researchers suggest that this simple, fast, and inexpensive colorimetric test has the potential to enhance the efficiency of early cervical cancer screening when compared to traditional detection methods. Furthermore, nanoparticles exhibit promising potential in fluorescence imaging of cervical cancer. This is attributed to their exellent absorption and fluorescence characteristics in the near-infrared region. Consequently, further research in this area is highly recommended (<xref ref-type="bibr" rid="B35">35</xref>). Based on the properties of different types of nanomaterials, including electrical conductivity, optical properties, magnetic or plasma properties, the combination of nano ions with traditional detection methods offers a new approach to enhance detection sensitivity and reduce costs in the diagnosis of cervical cancer. As nanotechnology continues to advance utilization of nanomaterials for detecting cervical cancer is expected to become more widespread. These nanomaterials are anticipated to outperform traditional detection methods in terms of sensitivity and reliability, while also mitigating operational challenges and minimizing the influence of the body environment on diagnostic outcomes. We could believe that this has the potential to revolutionize cervical tumors diagnosis.</p>
</sec>
<sec id="s4_2_1_3">
<label>4.2.1.3</label>
<title>Nanoparticles in photodynamic therapy</title>
<p>Nowadays, photodynamic therapy (PDT) has emerged as a groundbreaking treatment for cervical cancer in women. In contrast to conventional therapies like surgery, radiotherapy, and chemotherapy, which are associated with drawbacks such as extensive wounds, severe side effects, and drug resistance, PDT offers a minimally invasive approach that is resistant to multidrug resistance. This is due to its utilization of a clinical procedure that minimizes invasiveness, as well as a distinct toxicity mechanism targeting cancer cells, which sets it apart from chemotherapy (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). The cytotoxic effect of PDT on cancer cells primarily relies on the accumulation of photosensitizers (PS) in target tissues. When these PS are exposed to light of specific wavelengths matching their absorption spectrum, they transition from the ground state to an unstable excited state. This process generates singlet oxygen species, which further produce other reactive oxygen species (ROS). These ROS oxidize critical components within cancer cells, leading to an acute cellular stress response and ultimately resulting in cell death (<xref ref-type="bibr" rid="B38">38</xref>). Designing a reliable PS is crucial for the efficacy of PDT. Nanoparticles offer several advantages, including enhanced light absorption, higher photostability, and better biocompatibility. These properties assist in stabilizing and absorbing light, while minimizing side effects on the human body. Moreover, nanoparticles possess passive targeting capabilities, allowing them to accumulate intensively in tumor tissues through the enhanced permeability and retention (EPR) effects, thereby enhancing the effectiveness of the treatment (<xref ref-type="bibr" rid="B39">39</xref>). In order to enhance the targeting of tumors and improve the precision of treatment while minimizing damage to normal human cells, researchers have focused on targeting the tumor environment and various markers of cervical cancer. One approach is to load specific moieties onto specific nanoparticles, which has shown promising results (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>). Such as taking advantage of the elevated expression of molecular proteins, such as the CD44 receptor, in the tumor microenvironment, researchers utilized hyaluronic acid (HA) coupled with chloro e44 (Ce6) to create Ce6-coupled HA nanophotosensitizers. These nanophotosensitizers were specifically designed to target HeLa human cervical cancer cells by binding to the CD44 receptor (<xref ref-type="bibr" rid="B42">42</xref>). In addition, in a clinical trial conducted by Antonio Carlos Figueiredo Vendette et&#xa0;al., 12 patients were treated with PDT, and 11 of them achieved the desired results. Among the 11 patients, two received 2 treatments while the rest received only one treatment. Importantly, none of these patients experienced any cytotoxicity, indicating that the combination of nanotechnology and PDT holds promise as a safe treatment for cervical cancer. However, it should be noted that 11 of the patients in this trial had CIN type 1, while only 1 had CIN type 2. Therefore, further investigation is needed to explore the effectiveness of PDT in treating highly differentiated cervical cancer (<xref ref-type="bibr" rid="B43">43</xref>). However, there are still a number of problems in the practical application of PDT in the clinic: firstly, PDT is currently mainly applied to superficial tumors in the human body, with limited effect on deep tumors where light transmission is blocked; secondly, the photosensitization of the patient&#x2019;s skin after undergoing PDT is susceptible to side-effects; and lastly, due to the hydrophobicity of PS and the oxygen-dependence of PDT, the potential of PDT for the treatment of cervical cancer is currently limited (<xref ref-type="bibr" rid="B44">44</xref>&#x2013;<xref ref-type="bibr" rid="B47">47</xref>). After all, with the continuous advancement of nanotechnology, incorporating nanoparticles into PS may help overcome these challenges faced by PDT in clinical settings.</p>
</sec>
</sec>
<sec id="s4_2_2">
<label>4.2.2</label>
<title>Nanotechnology in the drug delivery of cervical cancer</title>
<p>The mechanism of nanotechnology in drug delivery for cervical cancer treatment involves the preparation of nanoscale drug carriers. These carriers encapsulate anticancer drugs and deliver them accurately to cervical cancer tumor cells through targeted delivery and release. By altering the surface properties and structure of nanodrug carriers, they can achieve targeted delivery and better interact with cancer cells. Once the nanodrug carrier reaches cancer cells, it gradually releases the drug into the tumor cells through its own special structure or drug release mechanism. This targeted and controlled release method improves drug efficacy, reduces side effects, and minimizes drug resistance during treatment. The application of nanotechnology offers more precise and effective drug delivery methods for the treatment of cervical cancer.</p>
<p>By altering the size, shape, and surface properties of drug carriers, nanotechnology has the potential to enhance the precision of drug delivery (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>). Chemotherapy is currently the primary treatment for tumors, but its efficiency is hampered by low solubility and lack of selectivity, which can increase toxicity to normal cells. Therefore, there is a need to focus on studying excellent carriers or developing new treatment strategies to address these issues and improve the effectiveness of chemotherapy (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B50">50</xref>). To overcome the limitations of chemotherapeutic agents, various synergistic therapeutic systems have been developed based on the characteristics of the tumor microenvironment. One such system is a targeted redox-sensitive micellar system (DOX/FCH) composed of ferrocene (Fc) and hyaluronic acid (HA), which enables the delivery of doxorubicin (DOX) for synergistic chemotherapy and chemodynamic therapy (CDT). The high affinity between HA and the CD44 receptor, which is highly expressed in human cervical cancer (HeLa) cells, allows DOX/FCH to accurately target the tumor site. The appropriate particle size facilitates the absorption of micelles by cells. Under a reducing environment that mimics the intracellular conditions of tumor cells, disulfide bonds are depolymerized, leading to approximately 50% release of DOX from DOX/FCH within 2 hours. The good biocompatibility of FCH in 3T3 cells and its evident cytotoxicity in HeLa cells suggest that FCH holds great potential as a nanocarrier. In addition, the cytotoxicity of DOX/FCH confirms the synergistic effect of CDT and DOX chemotherapy with FCH. Hence, DOX/FCH shows promising prospects for enhancing the efficacy of combination chemotherapy and CDT (<xref ref-type="bibr" rid="B51">51</xref>).</p>
<p>Nanotechnology has the potential to safeguard medications from the effects of the external environment and enhance their durability. For instance, in a specific research study, nanoparticles were used to encase the chemotherapy medication cisplatin, effectively preventing premature decomposition and metabolism within the body. This prolonged the drug&#x2019;s duration of action and improved its therapeutic efficacy (<xref ref-type="bibr" rid="B52">52</xref>). Small molecule induced DNA hydrogels with encapsulation and release properties are also effective in maintaining drug properties. DNA, a natural biopolymer, can assemble polyA tail DNA motif into hydrogel using small molecule cyanuric acid. Researchers have conducted experiments on the encapsulation of various substances, including a small chemotherapy drug, a fluorescent molecule, two proteins, and several nanoparticle formulations. The results demonstrated the release of doxorubicin, small fluorescent molecules, and fluorescent labeled antibodies (<xref ref-type="bibr" rid="B53">53</xref>).</p>
<p>Nanotechnology can also enhance the permeability of drugs, allowing them to traverse blood-tissue or tumor tissue barriers and access cervical cancer lesions. In a particular study, doxorubicin, a chemotherapy medication, exhibited improved permeability in cervical cancer lesions, leading to a significant enhancement in its anti-tumor efficacy (<xref ref-type="bibr" rid="B54">54</xref>). Due to the enhanced permeation and retention effects, stereocomplex micelles can selectively accumulate at the tumor site. In this study, a reliable drug delivery mechanism was created by combining enantiomeric 4-armed poly (ethylene glycol)&#x2013;poly (D-lactide) and poly (ethylene glycol)&#x2013;poly (L-lactide), aiming to regulate drug release and enhance tumor cell absorption for effective treatment of cervical carcinoma. The DOX-loaded micelles, including poly (D-lactide)-based micelle (PDM/DOX), poly (L-lactide)-based micelle (PLM/DOX), and stereocomplex micelle (SCM/DOX), all had sizes around 100 nm, which is suitable for the augmented permeability and retention (EPR) phenomenon. The effectiveness of DOX-loaded micelles, particularly SCM/DOX, in inhibiting tumors was confirmed in the U14 cervical carcinoma mouse model. The groups treated with DOX-loaded micelles, especially the SCM/DOX group, showed a significant increase in tumor cell death and necrosis. Moreover, these DOX-infused micelles demonstrated a remarkable reduction in DOX&#x2019;s systemic toxic effects. Therefore, SCM shows potential as an effective drug delivery mechanism for future treatments of cervical carcinoma (<xref ref-type="bibr" rid="B55">55</xref>).</p>
<p>Nanotechnology can be used to transport medications more efficiently to cervical cancer lesions, reducing the accumulation of drugs in healthy tissues and minimizing their adverse effects. For example, in a specific study, researchers utilized nanotechnology to encapsulate the chemotherapy medication doxorubicin within lipid nanoparticles, which helped mitigate the drug&#x2019;s harmful effects on healthy tissues such as the liver (<xref ref-type="bibr" rid="B56">56</xref>). Moreover, novel epirubicin-loaded nanoformulations were prepared from doxorubicin, which has a higher biocompatible therapeutic index (<xref ref-type="bibr" rid="B57">57</xref>). Cancer-specific drug delivery not only prevents adverse effects but also enhances drug accumulation in tumors. Therefore, surface modification of targeted selenium nanoparticles (SeNPs) with folic acid (FA) is an effective strategy for cancer treatment. FA-SeNPs nanoparticles are created by modifying SeNPs with folic acid, which binds to receptors overexpressed on the surface of cancer cells, including human cervical cancer HeLa cells, resulting in a tumor-targeting delivery vehicle. Subsequently, the anticancer drug DOX is loaded onto the surface of FA-SeNPs to improve its anti-tumor efficacy in the treatment of human cervical cancer (<xref ref-type="bibr" rid="B58">58</xref>).</p>
<p>Moreover, nanotechnology has the potential to create a combination of multiple drugs. Fytas et&#xa0;al. (Year) synthesized novel 1-(2-aryl-2-adamantyl)piperazine derivatives and evaluated their antitumor properties against HeLa cervical cancer <italic>in vitro</italic> (<xref ref-type="bibr" rid="B59">59</xref>). Chen et&#xa0;al. (Year) investigated the improvement of cancer treatment through the use of an acid-reactive cytotoxic peptide-doxorubicin compound (<xref ref-type="bibr" rid="B60">60</xref>). Nanotechnology has the potential to unite multiple drug carriers, enabling the implementation of multidrug combination therapy, which enhances therapeutic effectiveness and reduces tumor resistance to individual medications.</p>
<p>In the past time, although researchers have done many experiments on nanoparticles in drug delivery, the efficiency of translating research results into clinical applications is still low (<xref ref-type="bibr" rid="B61">61</xref>). Most of the applications of nanomedicines in cervical cancer are still in the laboratory stage. Therefore, it is becoming increasingly important to translate effective nanoparticle delivery methods from the experimental stage to clinical applications.</p>
<p>In conclusion, nanotechnology has the potential to enhance drug targeting, improve drug stability, increase drug permeability, and reduce drug side effects in the treatment of cervical cancer. This technology could offer a novel approach to treating cervical cancer.</p>
</sec>
</sec>
<sec id="s4_3">
<label>4.3</label>
<title>Future trend</title>
<p>The prominence graph of a keyword shows how long a certain keyword stays popular. The prominence graph allows us to obtain the possible trend in the future. From the <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>, we can learn that photothermal therapy, Indocyanine Green, etc may be a new direction for future research.</p>
<sec id="s4_3_1">
<label>4.3.1</label>
<title>Photothermal therapy</title>
<p>Despite radiotherapy being the primary treatment for cervical cancer, its potential side effects can significantly impact the outlook&#xa0;for patients. Recently, there has been a growing focus on near-infrared laser-induced photothermal therapy due to its advantageous biological safety characteristics (<xref ref-type="bibr" rid="B62">62</xref>). This therapy involves using light of a specific wavelengthto heat a photothermal agent, effectively killing tumor cells. <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref> demonstrates how nanoparticles are internalized in cells and convert light energy into heat, leading to the death of cancer cells. Photothermal therapy not&#xa0;only eliminates local tumor cells and minimizes damage to normal tissue cells, but also avoids the development of drug resistance, making it more effective than traditional radiotherapy. Nanotechnology advancements have enabled various nanomaterials to enhance the effectiveness of photothermal therapy and reduce its adverse effects through superior light absorption, conversion capacity, and biocompatibility. Moreover, certain nanomaterials can serve as both photothermal converters and innovative radiosensitizers, integrating radiotherapy and improving patient prognosis by enhancing photoelectric absorption efficiency and electron presence (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>). Apart from serving as photothermal converting agents for photothermal therapy, nanoparticles of appropriate size can effectively guide drugs or photothermal agents to the desired tumor site due to their increased permeability and retention effect (<xref ref-type="bibr" rid="B65">65</xref>). This nanomaterial-based transport approach has the potential to significantly enhance treatment precision and effectiveness, while minimizing harm to healthy tissue cells. In addition to passive targeting, magnetic targeting may emerge as a promising technique in clinical applications (<xref ref-type="bibr" rid="B66">66</xref>). Magnetic targeting technology relies on external conditions to enhance the accumulation of nanoparticles in the body, without altering the internal conditions, and has the capability to effectively eliminate tumor tissues (<xref ref-type="bibr" rid="B67">67</xref>). Currently, most experiments in this field are limited to <italic>in vitro</italic> cellular experiments or <italic>in vivo</italic> experiments in mice, with limited clinical data. However, nanoparticles have demonstrated promising results in both <italic>in vitro</italic> and ex vivo experiments. The application of nanotechnology in clinical photothermal therapy requires further investigation. Despite the recognition of nanoparticles&#x2019; potential in photothermal therapy, there is still much room for exploration. In the future, the focus may shift towards discovering nanomaterials that are safer, more precise, and more efficient, while also increasing the sensitivity of tumor cells to radiotherapy.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Mechanism of action of photothermal therapy.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1327851-g005.tif"/>
</fig>
</sec>
<sec id="s4_3_2">
<label>4.3.2</label>
<title>Indocyanine green</title>
<p>Indocyanine Green (ICG) is a fluorescent dye commonly used in clinical practice and has been studied for the treatment of cervical cancer in recent years. Its application mechanism can be divided into two aspects:</p>
<sec id="s4_3_2_1">
<label>4.3.2.1</label>
<title>Photothermal therapy</title>
<p>ICG exhibits good photosensitive properties and can absorb specific wavelength laser light sources. When exposed to a laser light source, ICG undergoes a photothermal effect, resulting in an increase in local temperature and causing thermal damage to cervical cancer cells. This therapy can induce tumor cell apoptosis, necrosis, and inhibit tumor growth.</p>
<p>For instance, researchers have explored the use of ICG-loaded lipid nanoparticles to induce intracellular thermal damage for effective treatment of cervical cancer (<xref ref-type="bibr" rid="B68">68</xref>). Additionally, polydopamine encapsulated novel indocyanine green therapeutic diagnostic nanoparticles have shown promise in enhancing the photothermal therapy of cervical cancer Hela cells (<xref ref-type="bibr" rid="B69">69</xref>&#x2013;<xref ref-type="bibr" rid="B71">71</xref>). The use of nanomaterials with high photothermal conversion efficiency and excellent biocompatibility can significantly improve the overall photothermal conversion efficiency and increase the accumulation of photoacoustic agents in tumors (<xref ref-type="bibr" rid="B72">72</xref>).</p>
</sec>
<sec id="s4_3_2_2">
<label>4.3.2.2</label>
<title>Fluorescence guided surgery</title>
<p>ICG exhibits strong fluorescence characteristics and can emit fluorescence under near-infrared spectroscopy. It is a near-infrared fluorescent dye that is biocompatible. When excited by external light with a wavelength of 750-800 nm, it emits longer wavelength near-infrared light, appearing green under fluorescence laparoscopy. In cervical cancer surgery, doctors can intravenously inject ICG into patients, taking advantage of its accumulation in tumor tissue to emit strong fluorescence signals under near-infrared spectroscopy. Fluorescence guided surgery can then be used by doctors to locate and remove tumors, enhancing the accuracy and thoroughness of the procedure. According to <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>, it can be observed that ICG-loaded nanoparticles accumulate in tumor cells after entering the body through blood vessels. Subsequently, when these tumor cells are exposed to infrared light, they exhibit a green fluorescence in the laparoscope.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Principles of IGG-guided fluorescence imaging.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1327851-g006.tif"/>
</fig>
<p>For instance, ICG dye can be utilized for sentinel lymph node (SLN) mapping in cervical cancer. SLN mapping is a viable surgical strategy that determines the necessity for radical lymph node dissection. It is based on the concept that SLN serves as the initial site of lymph node metastasis. If SLN is unaffected, it is theoretically assumed that the lymph nodes behind SLN should also be negative. The postoperative pathological confirmation rate of lymph node metastasis in most cervical cancer patients is approximately 24.16% (<xref ref-type="bibr" rid="B73">73</xref>). Therefore, pelvic lymph node dissection would not benefit them. The purpose of SLN biopsy is to avoid over-treatment by performing complete pelvic lymph node dissection on negative lymph nodes. This approach helps prevent complications associated with radical lymphadenectomy (<xref ref-type="bibr" rid="B74">74</xref>).</p>
<p>Combining indocyanine green (ICG) with nanoparticles can improve imaging localization. The use of ICG loaded with hyaluronic acid conjugated lactide-co-glycolide nanoparticles (HINPs) can enhance the target specificity of cervical cancer tumors. <italic>In vivo</italic> studies have demonstrated that HINPs enable near-infrared fluorescence imaging in cervical cancer cell lines. The efficiency of HINPs in delivering <italic>in vivo</italic> and the efficiency of free ICG in cervical cancer tumors were compared. Overall, HINPs have the potential to enhance NIR fluorescence image-guided surgery by assisting in the visualization of CD44-positive cervical cancer (<xref ref-type="bibr" rid="B75">75</xref>).</p>
<p>ICG imaging of lymph nodes is non-specific and cannot accurately distinguish between metastatic lymph nodes and inflammatory lymph nodes, resulting in a high false positive rate for tumor metastasis imaging. Additionally, ICG has inherent limitations such as poor water stability and low penetration depth, which affect its imaging performance. Furthermore, the lack of reactive groups in ICG makes it challenging to chemically synthesize it with other agents, such as targeting peptides. To overcome these limitations, active targeting using tumor-targeting ligands, such as targeting peptides, can be achieved by modifying the surface of nanoparticles. In this regard, the combination of the tumor metastasis-targeting peptide TMTP1 and ICG-loaded poly (ethylene glycol)-poly(lactide-co-glycolide acid) (PEG-PLGA) micelles was used to achieve active targeting. PEG-PLGA is a promising biodegradable polymer known for its biocompatibility, biodegradability, and sustained drug release properties, which contribute to more accurate imaging (<xref ref-type="bibr" rid="B76">76</xref>).</p>
<p>In summary, ICG can play a role in cervical cancer through two mechanisms: photothermal therapy and fluorescence guided surgery. Photothermal therapy utilizes the photosensitive properties of ICG to generate thermal effects and kill tumor cells through light irradiation. Fluorescence guided surgery utilizes the fluorescence characteristics of ICG to help doctors accurately locate and remove tumors during surgery, improving surgical effectiveness.</p>
</sec>
</sec>
</sec>
<sec id="s4_4">
<label>4.4</label>
<title>Limitation</title>
<p>The literature in our study may not be comprehensive. Firstly, our study focused only on WOOSC data and excluded data from other major search engines such as PubMed, EMBASE, and OVERE. Additionally, there is a language bias as we only retrieved articles published in English. Therefore, the articles found may not fully represent the body of research related to nanotechnology and cervical cancer. Secondly, high-quality papers published recently might not have received adequate attention due to low citation rates. These findings highlight the importance of regularly updating research. Although publications beyond September 20th, 2023 were excluded due to insufficient information, this review includes the majority of articles published between 2014 and 2023 in the field of cervical cancer and nanotechnology. Therefore, new data is unlikely to significantly impact the final results.</p>
</sec>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusions</title>
<p>After conducting a comprehensive analysis using various scientometric instruments, we have successfully characterized the nanotechnology literature in the field of cervical cancer. Additionally, we have reviewed the current trends in nanotechnology development in cervical cancer-related fields and identified the current research hotspots. Moreover, we have analyzed the potential future directions for research in this area. The continuous growth of literature in this field signifies its increasing global importance, with China emerging as the leading publisher in this domain. The current research hotspots revolve around &#x2018;nanoparticles&#x2019;, &#x2018;cervical cancer&#x2019;, and &#x2018;drug delivery&#x2019;, while the future research trend may involve the integration of nanotechnology with &#x2018;photothermal therapy&#x2019; and &#x2018;indocyanine green&#x2019;. It is evident that further research is required to fully explore the potential applications of nanotechnology in cervical cancer. The findings of these studies can provide valuable insights for new researchers in this field and contribute to the advancement of cervical cancer therapy.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>XS: Writing &#x2013; original draft. XL: Writing &#x2013; original draft. ZT: Writing &#x2013; review &amp; editing. LZ: Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Sichuan Provincial Medical Research Project Program (No. S19044); Chengdu Medical College Foundation Grant (No. CYZ18-14); the National College Student Innovation and Entrepreneurship Training Program Project (202213705036); Sichuan Provincial College Student Innovation and Entrepreneurship Training Program Project (S202313705089); the Development and Regeneration Key Laboratory of Sichuan Province(NoSYS13-006).</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>The authors are grateful to the reviewers for their thorough review of the manuscript, which allowed them to improve on the first draft.</p>
</ack>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>Author ZT was employed by the company  China National Nuclear Corporation 416 Hospital.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2024.1327851/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2024.1327851/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
<supplementary-material xlink:href="Image_1.jpeg" id="SF1" mimetype="image/jpeg">
<label>Supplementary Figure&#xa0;1</label>
<caption>
<p>
<bold>(A)</bold> Author co-authorship analysis carried on CiteSpace. <bold>(B)</bold> Analysis of co-cited authors carried on CiteSpace.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image_2.jpeg" id="SF2" mimetype="image/jpeg">
<label>Supplementary Figure&#xa0;2</label>
<caption>
<p>The collaboration network of institutions visualization map.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image_3.jpeg" id="SF3" mimetype="image/jpeg"/>
<supplementary-material xlink:href="Table_1.docx" id="ST1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannella</surname> <given-names>L</given-names>
</name>
<name>
<surname>Di Giuseppe</surname> <given-names>J</given-names>
</name>
<name>
<surname>Delli Carpini</surname> <given-names>G</given-names>
</name>
<name>
<surname>Grelloni</surname> <given-names>C</given-names>
</name>
<name>
<surname>Fichera</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sartini</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Hpv-negative adenocarcinomas of the uterine cervix: from molecular characterization to clinical implications</article-title>. <source>Int J Mol Sci</source> (<year>2022</year>) <volume>23</volume>:<elocation-id>15022</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms232315022</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zafar</surname> <given-names>A</given-names>
</name>
<name>
<surname>Alruwaili</surname> <given-names>NK</given-names>
</name>
<name>
<surname>Imam</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Alharbi</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Afzal</surname> <given-names>M</given-names>
</name>
<name>
<surname>Alotaibi</surname> <given-names>NH</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel nanotechnology approaches for diagnosis and therapy of breast, ovarian and cervical cancer in female: A review</article-title>. <source>J Drug Delivery Sci Technol</source> (<year>2021</year>) <volume>61</volume>:<elocation-id>102198</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jddst.2020.102198</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hegde</surname> <given-names>YM</given-names>
</name>
<name>
<surname>Theivendren</surname> <given-names>P</given-names>
</name>
<name>
<surname>Srinivas</surname> <given-names>G</given-names>
</name>
<name>
<surname>Palanivel</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shanmugam</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kunjiappan</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>A recent advancement in nanotechnology approaches for the treatment of cervical cancer</article-title>. <source>Anticancer Agents Med Chem</source> (<year>2023</year>) <volume>23</volume>:<fpage>37</fpage>&#x2013;<lpage>59</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/1871520622666220513160706</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>S-J</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>T-C</given-names>
</name>
<name>
<surname>Hung</surname> <given-names>C-F</given-names>
</name>
</person-group>. <article-title>Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research</article-title>. <source>J Gynecologic Oncol</source> (<year>2016</year>) <volume>27</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3802/jgo.2016.27.e51</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rob</surname> <given-names>L</given-names>
</name>
<name>
<surname>Robova</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chmel</surname> <given-names>R</given-names>
</name>
<name>
<surname>Komar</surname> <given-names>M</given-names>
</name>
<name>
<surname>Halaska</surname> <given-names>M</given-names>
</name>
<name>
<surname>Skapa</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Surgical options in early cervical cancer</article-title>. <source>Int J Hyperthermia</source> (<year>2012</year>) <volume>28</volume>:<fpage>489</fpage>&#x2013;<lpage>500</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3109/02656736.2012.675116</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Current status and future directions of cancer immunotherapy</article-title>. <source>J Cancer</source> (<year>2018</year>) <volume>9</volume>:<page-range>1773&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/jca.24577</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maney</surname> <given-names>V</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>The synergism of platinum-gold bimetallic nanoconjugates enhances 5-fluorouracil delivery in vitro</article-title>. <source>Pharmaceutics</source> (<year>2019</year>) <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pharmaceutics11090439</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>P</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Metal-organic frameworks/metal nanoparticles as smart nanosensing interfaces for electrochemical sensors applications: A mini-review</article-title>. <source>Front Bioeng Biotechnol</source> (<year>2023</year>) <volume>11</volume>:<elocation-id>1251713</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fbioe.2023.1251713</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mei</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>X</given-names>
</name>
<name>
<surname>He</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Recent progresses in electrochemical DNA biosensors for sars-cov-2 detection</article-title>. <source>Front Bioeng Biotechnol</source> (<year>2022</year>) <volume>10</volume>:<elocation-id>952510</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fbioe.2022.952510</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mei</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Electrochemical biosensors for foodborne pathogens detection based on carbon nanomaterials: recent advances and challenges</article-title>. <source>Food Bioprocess Technol</source> (<year>2022</year>) <volume>15</volume>:<fpage>498</fpage>&#x2013;<lpage>513</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11947-022-02759-7</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>D</given-names>
</name>
<name>
<surname>Tong</surname> <given-names>Q-X</given-names>
</name>
</person-group>. <article-title>Carbon dots/&#x391;-fe2o3-fe3o4 nanocomposite: efficient synthesis and application as a novel electrochemical aptasensor for the ultrasensitive determination of aflatoxin B1</article-title>. <source>Food Chem</source> (<year>2022</year>) <volume>373</volume>:<elocation-id>131415</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.foodchem.2021.131415</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>P</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Nanoparticle delivery of active traditional chinese medicine ingredients: A new strategy for the treatment of liver cancer</article-title>. <source>Curr Pharm Biotechnol</source> (<year>2023</year>) <volume>24</volume>:<page-range>1630&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/1389201024666230313151316</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anwanwan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>S</given-names>
</name>
<name>
<surname>Saikam</surname> <given-names>V</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Challenges in liver cancer and possible treatment approaches</article-title>. <source>Biochim Biophys Acta Rev Cancer</source> (<year>2020</year>) <volume>1873</volume>:<elocation-id>188314</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbcan.2019.188314</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>A step-by-step multiple stimuli-responsive metal-phenolic network prodrug nanoparticles for chemotherapy</article-title>. <source>Nano Res</source> (<year>2022</year>) <volume>15</volume>:<page-range>1205&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12274-021-3626-2</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakrania</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>G</given-names>
</name>
<name>
<surname>Bhat</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Nanomedicine in hepatocellular carcinoma: A new frontier in targeted cancer treatment</article-title>. <source>Pharmaceutics</source> (<year>2021</year>) <volume>14</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pharmaceutics14010041</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>S</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>J</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Camptothecin delivery <italic>via</italic> tumor-derived exosome for radiosensitization by cell cycle regulation on patient-derived xenograft mice</article-title>. <source>Front Bioeng Biotechnol</source> (<year>2022</year>) <volume>10</volume>:<elocation-id>876641</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fbioe.2022.876641</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sykes</surname> <given-names>PD</given-names>
</name>
<name>
<surname>Neoptolemos</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Costello</surname> <given-names>E</given-names>
</name>
<name>
<surname>Halloran</surname> <given-names>CM</given-names>
</name>
</person-group>. <article-title>Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer</article-title>. <source>Expert Rev Gastroenterol Hepatol</source> (<year>2012</year>) <volume>6</volume>:<page-range>343&#x2013;56</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1586/egh.12.13</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Song</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Visualizing a field of research: A methodology of systematic scientometric reviews</article-title>. <source>PloS One</source> (<year>2019</year>) <volume>14</volume>:<elocation-id>e0223994</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0223994</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Research trends and most influential clinical studies on anti-pd1/pdl1 immunotherapy for cancers: A bibliometric analysis</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>862084</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.862084</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Sheng</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Tracing the scientific outputs in the field of ebola research based on publications in the web of science</article-title>. <source>BMC Res Notes</source> (<year>2016</year>) <volume>9</volume>:<fpage>221</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13104-016-2026-2</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Knowledge mapping of platform research: A visual analysis using vosviewer and citespace</article-title>. <source>Electronic Commerce Res</source> (<year>2022</year>) <volume>22</volume>:<fpage>787</fpage>&#x2013;<lpage>809</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10660-020-09410-7</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rasouli</surname> <given-names>E</given-names>
</name>
<name>
<surname>Shahnavaz</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Basirun</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Rezayi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Avan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ghayour-Mobarhan</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Advancements in electrochemical DNA sensor for detection of human papilloma virus - a review</article-title>. <source>Analytical Biochem</source> (<year>2018</year>) <volume>556</volume>:<page-range>136&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ab.2018.07.002</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Senapati</surname> <given-names>S</given-names>
</name>
<name>
<surname>Klacsmann</surname> <given-names>F</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>HC</given-names>
</name>
<etal/>
</person-group>. <article-title>Current technologies and recent developments for screening of hpv-associated cervical and oropharyngeal cancers</article-title>. <source>Cancers (Basel)</source> (<year>2016</year>) <volume>8</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers8090085</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Chinchulkar</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Patra</surname> <given-names>P</given-names>
</name>
<name>
<surname>Dehariya</surname> <given-names>D</given-names>
</name>
<name>
<surname>Appidi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Rengan</surname> <given-names>AK</given-names>
</name>
</person-group>. <article-title>22 - Gold Nanoparticle&#x2013;Based Biosensing Applications and Fundamentals of Sensor Technology: Principles and Novel Designs</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Barhoum</surname> <given-names>A</given-names>
</name>
<name>
<surname>Altintas</surname> <given-names>Z</given-names>
</name>
</person-group>, editors. <source>Fundamentals of Sensor Technology</source> <publisher-loc>Sawston, Cambridge</publisher-loc>: <publisher-name>Woodhead Publishing</publisher-name> (<year>2023</year>). p. <fpage>669</fpage>&#x2013;<lpage>723</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/B978-0-323-88431-0.00014-4</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foo</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Gopinath</surname> <given-names>SCB</given-names>
</name>
</person-group>. <article-title>Feasibility of graphene in biomedical applications</article-title>. <source>BioMed Pharmacother</source> (<year>2017</year>) <volume>94</volume>:<page-range>354&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2017.07.122</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahmoodi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Rezayi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rasouli</surname> <given-names>E</given-names>
</name>
<name>
<surname>Avan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gholami</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ghayour Mobarhan</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Early-stage cervical cancer diagnosis based on an ultra-sensitive electrochemical DNA nanobiosensor for hpv-18 detection in real samples</article-title>. <source>J Nanobiotechnology</source> (<year>2020</year>) <volume>18</volume>:<elocation-id>11</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12951-020-0577-9</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Cheung</surname> <given-names>YF</given-names>
</name>
<name>
<surname>Siu-Chung Tam</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lok</surname> <given-names>CN</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ng</surname> <given-names>KM</given-names>
</name>
</person-group>. <article-title>Plasmonic metal nanoparticles as efficient mass tags for ion signal amplification and ultrasensitive detection of protein markers</article-title>. <source>Anal Chim Acta</source> (<year>2019</year>) <volume>1055</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.aca.2018.12.057</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tam</surname> <given-names>TS-C</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>Y-H</given-names>
</name>
<name>
<surname>Lok</surname> <given-names>C-N</given-names>
</name>
<name>
<surname>Au-Yeung</surname> <given-names>HY</given-names>
</name>
<name>
<surname>Ni</surname> <given-names>W-X</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>X-L</given-names>
</name>
<etal/>
</person-group>. <article-title>Surface optimization of gold nanoparticle mass tags for the sensitive detection of protein biomarkers <italic>via</italic> immuno-capture li-ms</article-title>. <source>Analyst</source> (<year>2020</year>) <volume>145</volume>:<page-range>6237&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1039/D0AN01121E</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sikaroodi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Galachiantz</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Baranova</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Tumor markers: the potential of &amp;#X201c;Omics&amp;#X201d; approach</article-title>. <source>Curr Mol Med</source> (<year>2010</year>) <volume>10</volume>:<page-range>249&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/156652410790963277</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lakshmipriya</surname> <given-names>T</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gopinath</surname> <given-names>SCB</given-names>
</name>
</person-group>. <article-title>Squamous cell carcinoma biomarker sensing on a strontium oxide-modified interdigitated electrode surface for the diagnosis of cervical cancer</article-title>. <source>BioMed Res Int</source> (<year>2019</year>) <volume>2019</volume>:<elocation-id>2807123</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/2807123</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Du</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Simultaneous electrochemical detection of cervical cancer markers using reduced graphene oxide-tetraethylene pentamine as electrode materials and distinguishable redox probes as labels</article-title>. <source>Biosensors Bioelectronics</source> (<year>2014</year>) <volume>54</volume>:<page-range>634&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bios.2013.11.042</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gopinath</surname> <given-names>SCB</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Coordination of nanoconjugation with an antigen/antibody for efficient detection of gynecological tumors</article-title>. <source>J Analytical Methods Chem</source> (<year>2020</year>) <volume>2020</volume>:<elocation-id>6528572</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2020/6528572</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chela-Flores</surname> <given-names>J</given-names>
</name>
<name>
<surname>Migoni</surname> <given-names>RL</given-names>
</name>
</person-group>. <article-title>Cg methylation in DNA transcription</article-title>. <source>Int J Theor Phys</source> (<year>1990</year>) <volume>29</volume>:<page-range>853&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/BF00675102</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liou</surname> <given-names>YL</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>YN</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>ZR</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>HH</given-names>
</name>
</person-group>. <article-title>Real-time colorimetric detection of DNA methylation of the pax1 gene in cervical scrapings for cervical cancer screening with thiol-labeled pcr primers and gold nanoparticles</article-title>. <source>Int J Nanomedicine</source> (<year>2016</year>) <volume>11</volume>:<page-range>5335&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/ijn.S116288</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>T</given-names>
</name>
<name>
<surname>Alimu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>R</given-names>
</name>
<name>
<surname>Alifu</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Liposome-loaded targeted theranostic fluorescent nano-probes for diagnosis and treatment of cervix carcinoma</article-title>. <source>J Biomed Nanotechnology</source> (<year>2022</year>) <volume>18</volume>:<page-range>1289&#x2013;301</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1166/jbn.2022.3332</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Porphine functionalized nanoparticles of star-shaped poly(&#x395;-caprolactone)-B-D-&#x391;-tocopheryl polyethylene glycol 1000 succinate biodegradable copolymer for chemophotodynamic therapy on cervical cancer</article-title>. <source>Acta Biomater</source> (<year>2015</year>) <volume>26</volume>:<page-range>145&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.actbio.2015.08.016</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>S-R</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>Y-J</given-names>
</name>
</person-group>. <article-title>Hydrophilic chlorin E6-poly(Amidoamine) dendrimer nanoconjugates for enhanced photodynamic therapy</article-title>. <source>Nanomaterials</source> (<year>2018</year>) <volume>8</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/nano8060445</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deni</surname> <given-names>E</given-names>
</name>
<name>
<surname>Zamarr&#xf3;n</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bonaccorsi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Carmen Carre&#xf1;o</surname> <given-names>M</given-names>
</name>
<name>
<surname>Juarranz</surname> <given-names>&#xc1;</given-names>
</name>
<name>
<surname>Puntoriero</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Glucose-functionalized amino-opes as biocompatible photosensitizers in pdt</article-title>. <source>Eur J Medicinal Chem</source> (<year>2016</year>) <volume>111</volume>:<fpage>58</fpage>&#x2013;<lpage>71</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejmech.2016.01.041</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeda</surname> <given-names>H</given-names>
</name>
<name>
<surname>Nakamura</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>The epr effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo</article-title>. <source>Adv Drug Delivery Rev</source> (<year>2013</year>) <volume>65</volume>:<page-range>71&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.addr.2012.10.002</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steichen</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Caldorera-Moore</surname> <given-names>M</given-names>
</name>
<name>
<surname>Peppas</surname> <given-names>NA</given-names>
</name>
</person-group>. <article-title>A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics</article-title>. <source>Eur J Pharm Sci</source> (<year>2013</year>) <volume>48</volume>:<page-range>416&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejps.2012.12.006</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bazak</surname> <given-names>R</given-names>
</name>
<name>
<surname>Houri</surname> <given-names>M</given-names>
</name>
<name>
<surname>El Achy</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kamel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Refaat</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Cancer active targeting by nanoparticles: A comprehensive review of literature</article-title>. <source>J Cancer Res Clin Oncol</source> (<year>2015</year>) <volume>141</volume>:<page-range>769&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00432-014-1767-3</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>H</given-names>
</name>
<name>
<surname>Jeong</surname> <given-names>Y-IL</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>HS</given-names>
</name>
</person-group>. <article-title>Cd44 receptor-mediated/reactive oxygen species-sensitive delivery of nanophotosensitizers against cervical cancer cells</article-title>. <source>Int J Mol Sci</source> (<year>2022</year>) <volume>23</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms23073594</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vendette</surname> <given-names>ACF</given-names>
</name>
<name>
<surname>Piva</surname> <given-names>HL</given-names>
</name>
<name>
<surname>Muehlmann</surname> <given-names>LA</given-names>
</name>
<name>
<surname>de Souza</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Tedesco</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Azevedo</surname> <given-names>RB</given-names>
</name>
</person-group>. <article-title>Clinical treatment of intra-epithelia cervical neoplasia with photodynamic therapy</article-title>. <source>Int J Hyperthermia</source> (<year>2020</year>) <volume>37</volume>:<page-range>50&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/02656736.2020.1804077</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garland</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Cassidy</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Woolfson</surname> <given-names>D</given-names>
</name>
<name>
<surname>Donnelly</surname> <given-names>RF</given-names>
</name>
</person-group>. <article-title>Designing photosensitizers for photodynamic therapy: strategies, challenges and promising developments</article-title>. <source>Future Med Chem</source> (<year>2009</year>) <volume>1</volume>:<page-range>667&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4155/fmc.09.55</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Meyers</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Musani</surname> <given-names>AI</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tagg</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Photodynamic therapy for treatment of solid tumors&#x2013;potential and technical challenges</article-title>. <source>Technol Cancer Res Treat</source> (<year>2008</year>) <volume>7</volume>:<page-range>309&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/153303460800700405</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yoon</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Supramolecular agents for combination of photodynamic therapy and other treatments</article-title>. <source>Chem Sci</source> (<year>2021</year>) <volume>12</volume>:<page-range>7248&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1039/D1SC01125A</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yoon</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Supramolecular photosensitizers rejuvenate photodynamic therapy</article-title>. <source>Chem Soc Rev</source> (<year>2018</year>) <volume>47</volume>:<page-range>1174&#x2013;88</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1039/C7CS00594F</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khanna</surname> <given-names>N</given-names>
</name>
<name>
<surname>Chatterji</surname> <given-names>T</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pandey</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Application of stimuli responsive nanocomposites in drug delivery and theranostics to counter cancer proliferation and drug resistance</article-title>. <source>J Drug Delivery Sci Technol</source> (<year>2023</year>) <volume>88</volume>:<elocation-id>104958</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jddst.2023.104958</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>B</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>D</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zou</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Paclitaxel-loaded lignin particle encapsulated into electrospun pva/pvp composite nanofiber for effective cervical cancer cell inhibition</article-title>. <source>Nanotechnology</source> (<year>2021</year>) <volume>32</volume>:<fpage>015101</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1088/1361-6528/abb55a</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pourmadadi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ghaemi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Shamsabadipour</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rajabzadeh-Khosroshahi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shaghaghi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rahdar</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Nanoparticles loaded with daunorubicin as an advanced tool for cancer therapy</article-title>. <source>Eur J Medicinal Chem</source> (<year>2023</year>) <volume>258</volume>:<elocation-id>115547</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115547</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>P</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>B</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Redox-sensitive hyaluronic acid-ferrocene micelles delivering doxorubicin for enhanced tumor treatment by synergistic chemo/chemodynamic therepay</article-title>. <source>J Drug Delivery Sci Technol</source> (<year>2022</year>) <volume>77</volume>:<elocation-id>103851</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jddst.2022.103851</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kousar</surname> <given-names>K</given-names>
</name>
<name>
<surname>Naseer</surname> <given-names>F</given-names>
</name>
<name>
<surname>Abduh</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Kakar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gul</surname> <given-names>R</given-names>
</name>
<name>
<surname>Anjum</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Green synthesis of hyaluronic acid coated, thiolated chitosan nanoparticles for cd44 targeted delivery and sustained release of cisplatin in cervical carcinoma</article-title>. <source>Front Pharmacol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>1073004</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2022.1073004</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nandu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Uyar</surname> <given-names>TB</given-names>
</name>
<name>
<surname>Royzen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yigit</surname> <given-names>MV</given-names>
</name>
</person-group>. <article-title>Small molecule-induced DNA hydrogel with encapsulation and release properties</article-title>. <source>Chem Commun (Camb)</source> (<year>2020</year>) <volume>56</volume>:<page-range>7313&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1039/d0cc03439h</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabizon</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Patil</surname> <given-names>Y</given-names>
</name>
<name>
<surname>La-Beck</surname> <given-names>NM</given-names>
</name>
</person-group>. <article-title>New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy</article-title>. <source>Drug Resist Update</source> (<year>2016</year>) <volume>29</volume>:<fpage>90</fpage>&#x2013;<lpage>106</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.drup.2016.10.003</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xiu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ge</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Controlled drug delivery by polylactide stereocomplex micelle for cervical cancer chemotherapy</article-title>. <source>Front Pharmacol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>930</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2018.00930</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gheibihayat</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Jaafari</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Hatamipour</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sahebkar</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Improvement of the pharmacokinetic characteristics of liposomal doxorubicin using cd47 biomimickry</article-title>. <source>J Pharm Pharmacol</source> (<year>2021</year>) <volume>73</volume>:<page-range>169&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/jpp/rgaa005</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pourmadadi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ostovar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ruiz-Pulido</surname> <given-names>G</given-names>
</name>
<name>
<surname>Hassan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Souri</surname> <given-names>M</given-names>
</name>
<name>
<surname>Manicum</surname> <given-names>A-LE</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel epirubicin-loaded nanoformulations: advancements in polymeric nanocarriers for efficient targeted cellular and subcellular anticancer drug delivery</article-title>. <source>Inorganic Chem Commun</source> (<year>2023</year>) <volume>155</volume>:<elocation-id>110999</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.inoche.2023.110999</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hua</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Delivery of doxorubicin for human cervical carcinoma targeting therapy by folic acid-modified selenium nanoparticles</article-title>. <source>Int J Mol Sci</source> (<year>2018</year>) <volume>19</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms19113582</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fytas</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zoidis</surname> <given-names>G</given-names>
</name>
<name>
<surname>Tsotinis</surname> <given-names>A</given-names>
</name>
<name>
<surname>Fytas</surname> <given-names>G</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Akhtar</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel 1-(2-aryl-2-adamantyl)Piperazine derivatives with antiproliferative activity</article-title>. <source>Eur J Medicinal Chem</source> (<year>2015</year>) <volume>93</volume>:<page-range>281&#x2013;90</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejmech.2015.02.021</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>G</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Enhanced cancer treatment by an acid-sensitive cytotoxic peptide-doxorubicin conjugate</article-title>. <source>J Drug Delivery Sci Technol</source> (<year>2020</year>) <volume>60</volume>:<elocation-id>102048</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jddst.2020.102048</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalaydina</surname> <given-names>R-V</given-names>
</name>
<name>
<surname>Bajwa</surname> <given-names>K</given-names>
</name>
<name>
<surname>Qorri</surname> <given-names>B</given-names>
</name>
<name>
<surname>DeCarlo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Szewczuk</surname> <given-names>MR</given-names>
</name>
</person-group>. <article-title>Recent advances in &#x201c;smart&#x201d; delivery systems for extended drug release in cancer therapy</article-title>. <source>Int J Nanomed</source> (<year>2018</year>) <volume>13</volume>:<page-range>4727&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/ijn.S168053</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cole</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Mirin</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Knight</surname> <given-names>MW</given-names>
</name>
<name>
<surname>Goodrich</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Halas</surname> <given-names>NJ</given-names>
</name>
</person-group>. <article-title>Photothermal efficiencies of nanoshells and nanorods for clinical therapeutic applications</article-title>. <source>J Phys Chem C</source> (<year>2009</year>) <volume>113</volume>:<page-range>12090&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/jp9003592</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>X</given-names>
</name>
<name>
<surname>El-Sayed</surname> <given-names>IH</given-names>
</name>
<name>
<surname>Qian</surname> <given-names>W</given-names>
</name>
<name>
<surname>El-Sayed</surname> <given-names>MA</given-names>
</name>
</person-group>. <article-title>Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods</article-title>. <source>J Am Chem Soc</source> (<year>2006</year>) <volume>128</volume>:<page-range>2115&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/ja057254a</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hainfeld</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Dilmanian</surname> <given-names>FA</given-names>
</name>
<name>
<surname>Slatkin</surname> <given-names>DN</given-names>
</name>
<name>
<surname>Smilowitz</surname> <given-names>HM</given-names>
</name>
</person-group>. <article-title>Radiotherapy enhancement with gold nanoparticles</article-title>. <source>J Pharm Pharmacol</source> (<year>2010</year>) <volume>60</volume>:<page-range>977&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1211/jpp.60.8.0005</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucarini</surname> <given-names>M</given-names>
</name>
<name>
<surname>Franchi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Pedulli</surname> <given-names>GF</given-names>
</name>
<name>
<surname>Pengo</surname> <given-names>P</given-names>
</name>
<name>
<surname>Scrimin</surname> <given-names>P</given-names>
</name>
<name>
<surname>Pasquato</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Epr study of dialkyl nitroxides as probes to investigate the exchange of solutes between the ligand shell of monolayers of protected gold nanoparticles and aqueous solutions</article-title>. <source>J Am Chem Soc</source> (<year>2004</year>) <volume>126</volume>:<page-range>9326&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/ja048554f</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McBain</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Yiu</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Dobson</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Magnetic nanoparticles for gene and drug delivery</article-title>. <source>Int J Nanomedicine</source> (<year>2008</year>) <volume>3</volume>:<page-range>169&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/ijn.s1608</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Core-shell magnetic gold nanoparticles for magnetic field-enhanced radio-photothermal therapy in cervical cancer</article-title>. <source>Nanomaterials</source> (<year>2017</year>) <volume>7</volume>:<elocation-id>111</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/nano7050111</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname> <given-names>Q-Q</given-names>
</name>
<name>
<surname>Li</surname> <given-names>B-L</given-names>
</name>
</person-group>. <article-title>Cinnamaldehyde and indocyanine green loaded lipid nanoparticles induced intracellular oxidative/thermal stress damage for effective cervical cancer therapy</article-title>. <source>Micro Nano Lett</source> (<year>2022</year>) <volume>17</volume>:<page-range>175&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1049/mna2.12120</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>T</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Du</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Alimu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>LJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Polydopamine encapsulated new indocyanine green theranostic nanoparticles for enhanced photothermal therapy in cervical cancer hela cells</article-title>. <source>Front Bioeng Biotechnol</source> (<year>2022</year>) <volume>10</volume>:<elocation-id>984166</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fbioe.2022.984166</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname> <given-names>T</given-names>
</name>
<name>
<surname>Alimu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>LX</given-names>
</name>
<name>
<surname>Du</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Ppix/ir-820 dual-modal therapeutic agents for enhanced pdt/ptt synergistic therapy in cervical cancer</article-title>. <source>ACS Omega</source> (<year>2022</year>) <volume>7</volume>:<page-range>44643&#x2013;56</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acsomega.2c02977</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>R</given-names>
</name>
<name>
<surname>Alifu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Du</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Heng</surname> <given-names>YQ</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Indocyanine green-based theranostic nanoplatform for nir fluorescence image-guided chemo/photothermal therapy of cervical cancer</article-title>. <source>Int J Nanomed</source> (<year>2021</year>) <volume>16</volume>:<page-range>4847&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/ijn.S318678</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Functional nanomaterials for phototherapies of cancer</article-title>. <source>Chem Rev</source> (<year>2014</year>) <volume>114</volume>:<page-range>10869&#x2013;939</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/cr400532z</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuchs</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hamann</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Schulenburg</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kn&#xfc;pfer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Osmonov</surname> <given-names>D</given-names>
</name>
<name>
<surname>L&#xfc;tzen</surname> <given-names>U</given-names>
</name>
<etal/>
</person-group>. <article-title>[Sentinel lymph node biopsy for penile carcinoma : assessment of reliability]</article-title>. <source>Urologe A</source> (<year>2013</year>) <volume>52</volume>:<page-range>1447&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00120-013-3166-9</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>DS</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>ZM</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Application of carbon nanoparticles in laparoscopic sentinel lymph node detection in patients with early-stage cervical cancer</article-title>. <source>PloS One</source> (<year>2017</year>) <volume>12</volume>:<elocation-id>e0183834</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0183834</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Park</surname> <given-names>S</given-names>
</name>
<name>
<surname>Park</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Park</surname> <given-names>C</given-names>
</name>
<name>
<surname>Key</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Indocyanine green-loaded plga nanoparticles conjugated with hyaluronic acid improve target specificity in cervical cancer tumors</article-title>. <source>Yonsei Med J</source> (<year>2021</year>) <volume>62</volume>:<page-range>1042&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3349/ymj.2021.62.11.1042</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname> <given-names>R</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Tmtp1-modified indocyanine green-loaded polymeric micelles for targeted imaging of cervical cancer and metastasis sentinel lymph node <italic>in vivo</italic>
</article-title>. <source>Theranostics</source> (<year>2019</year>) <volume>9</volume>:<page-range>7325&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/thno.35346</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>